08th week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210052640 | TEMPERATURE-CONTROLLED SEMIOCHEMICAL COMPOSITION DIFFUSERS - The present invention describes new formulations of semiochemical compounds for mammals in wick diffusers particularly effective in controlling the diffusion of several semiochemicals having different volatilities over long periods of time and independently of the temperature and humidity conditions. | 2021-02-25 |
20210052641 | PRE-CONDITIONED EXTRACELLULAR VESICLES AND METHODS OF PRODUCTION - A method for treating inflammatory diseases is provided. The method may include administering to a subject in need thereof a therapeutically effective amount of isolated extracellular vesicles or exosomes obtained from mesenchymal stem cells pre-conditioned with at least TNF-α. The isolated extracellular vesicles or exosomes may exhibit (a) enhanced expression of flotillin-1, (b) enhanced expression of CD73, or (c) enhanced expression of IDO. A method of isolating extracellular vesicles or exosomes capable of treating an inflammatory disease is also provided, wherein the method may include (a) culturing stem cells in a growth medium, (b) then culturing the stem cells in a starve medium supplemented with at least TNF-α, and (c) separating exosomes or extracellular vesicles from the culture. Cultures suitable for treatment are also provided. | 2021-02-25 |
20210052642 | METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS - Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer. | 2021-02-25 |
20210052643 | MODIFIED MACROPHAGES AND MACROPHAGE PRECURSORS AND ASSOCIATED METHODS - Described herein are macrophages or macrophage precursor cells lacking functional expression of MHC genes. The macrophages may express HLA-G or a modified MHC gene that does not elicit an immune response in an allogeneic subject but remains recognized by NK cells. The cells may further comprise a chimeric antigen receptor. | 2021-02-25 |
20210052644 | METHOD FOR TREATING GLIOBLASTOMA - Disclosed is a method for treating glioblastoma or other brain tumors. The method includes steps of preparing cells comprising a chimeric antigen receptor (CAR) molecule and administering to a mammal in need thereof an effective amount of the prepared cells. Also disclosed is that the CAR molecule contains an antigen binding domain that binds to the tumor antigen associated with the glioblastoma or other brain tumors, and the tumor antigen is carbonic anhydrase IX. | 2021-02-25 |
20210052645 | Innate Targeting of Adoptive Cellular Therapies - Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor. | 2021-02-25 |
20210052646 | NUCLEIC-ACID CONTAINING LIPID NANO-PARTICLE AND USE THEREOF - The present invention provides a lipid nanoparticle containing the following (a) to (c): | 2021-02-25 |
20210052647 | TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 - Disclosed are nucleic acids and polypeptides which provide the co-expression of interleukin (IL)-21 and IL-15 by a host cell, each interleukin being bound to the cell membrane by a cell membrane anchor moiety. Also disclosed are related recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer. | 2021-02-25 |
20210052648 | METHOD OF PRODUCING LEUKOCYTES USING PTPN2 INHIBITION FOR ADOPTIVE CELL TRANSFER - The present invention generally relates to methods of preparing leukocytes, particularly T cells, ex vivo for use in immunotherapy, particularly cancer immunotherapy. More specifically, the invention relates to methods for the preparation of leukocytes exhibiting cytotoxic properties for use in adoptive cell transfer. The invention also relates to cells and compositions including them for cancer immunotherapy. The invention also relates to methods of immunotherapy, particularly cancer immunotherapy. The present invention relates to a method for producing a leukocyte that has an enhanced capacity for killing a target cell, the method including contacting the leukocyte with a PTPN2 inhibitor in conditions for enabling the inhibitor to inactivate PTPN2 in the leukocyte, thereby producing a leukocyte that has an enhanced capacity for killing a target cell. Preferably, the leukocyte is contacted with the PTPN2 inhibitor in the absence of a T helper cell. | 2021-02-25 |
20210052649 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY - The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described. | 2021-02-25 |
20210052650 | ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE - Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells. | 2021-02-25 |
20210052651 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-02-25 |
20210052652 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-02-25 |
20210052653 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-02-25 |
20210052654 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-02-25 |
20210052655 | PRODUCTION AND USE OF RED BLOOD CELLS - The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation. | 2021-02-25 |
20210052656 | PROCESSES FOR MAKING AND USING A MESENCHYMAL STEM CELL DERIVED SECRETOME - The present application provides methods and processes for making and using a mesenchymal stem cell secretome, as well as methods for treating ocular conditions and/disorders with the mesenchymal stem cell secretome described herein. | 2021-02-25 |
20210052657 | MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR TREATING AND DIAGNOSING FIBROTIC DISEASES - The described invention provides compositions and methods for treating a fibrotic condition in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising synthetic extracellular vesicles (EVs) and a pharmaceutically acceptable carrier. | 2021-02-25 |
20210052658 | POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY - A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available. | 2021-02-25 |
20210052659 | PHARMACEUTICAL COMPOSITION COMPRISING ISOLATED MITOCHONDRIA FOR PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS - The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis. | 2021-02-25 |
20210052660 | NEURAL STEM CELL COMPOSITIONS INCLUDING CHIMERIC POXVIRUSES FOR CANCER TREATMENT - Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and a replication-competent oncolytic virus such as conditionally replication-competent chimeric orthopoxvirus (CF33). The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer. | 2021-02-25 |
20210052661 | COMPOSITIONS AND METHODS FOR REPAIRING CARTILAGE DEFECTS - The present disclosure provides compositions and methods for repairing cartilage defects. | 2021-02-25 |
20210052662 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION - The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site. | 2021-02-25 |
20210052663 | Compositions and Methods for Treatment of Cardiovascular Disorders - Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties. | 2021-02-25 |
20210052664 | TREATMENT OF INTERVERTEBRAL DISC DEGENERATION - The present application discloses a method for preventing or retarding degeneration of intervertebral disc at an intervertebral disc defect site, which includes injecting a mammalian connective tissue cell into the intervertebral disc defect site. | 2021-02-25 |
20210052665 | METHODS TO INDUCE TERMINAL DIFFERENTIATION IN STEM CELLS BY INTERFERING WITH DNA REPLICATION, METHODS OF INDUCING PANCREATIC DIFFERENTIATION, AND DIFFERENTIATED CELLS OBTAINED THEREOF - The current invention provides for methods and systems of inducing cell cycle exit and terminal differentiation in stem cells undergoing differentiation into various mature cell types in particular pancreatic endocrine cells. The current invention also provides for methods and systems of inducing differentiation of pancreatic endocrine cells from stem cells. The invention also provides for the cells produced by the methods that are suitable for transplantation or grafting into a subject for the prevention and/or treatment of disease, and useful for basic research and drug testing. | 2021-02-25 |
20210052666 | SYSTEMS AND METHODS FOR THROMBOSIS PREVENTION - The disclosure provides a composition for inhibiting thrombosis. The composition includes 5 to 25% by weight of Fish Oil, 15 to 55% by weight of Willow Bark Extract, and 0.2 to 5% by weight of Vitamin E. | 2021-02-25 |
20210052667 | METHODS FOR PRODUCING COMPOSITIONS CONTAINING PLASMALOGEN - Provided is a method for producing a composition containing plasmalogen derived from a plasmalogen-containing animal tissue, the method being without significantly decreasing an amount of plasmalogen derived the plasmalogen-containing animal tissue. A method for producing a composition containing plasmalogen derived from an animal tissue, the method comprising: (A) concentrating an alcohol extract of a plasmalogen-containing animal tissue, and (B) after diluting a concentrated product obtained by (A), allowing to stand under refrigeration. | 2021-02-25 |
20210052668 | HONEY-BASED GEL COMPOSITION - A honey based composition is described. The composition includes a mixture of honey, a short chain fatty alcohol and a fatty ester or wax. The composition has applications for use in wound dressings and in one embodiment may be a gel. The composition has a higher than expected storage stability, remaining stable for many weeks when held at elevated temperatures and retains all of the other desirable characteristics including anti-microbial activity. | 2021-02-25 |
20210052669 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERS USING LACHNOSPIRACEAE BACTERIA - Provided herein are methods and compositions related to | 2021-02-25 |
20210052670 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF OXALATE-RELATED DISORDERS - The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria | 2021-02-25 |
20210052671 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides a composition comprising a bacterial strain of the genus | 2021-02-25 |
20210052672 | USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS - Methods of treating neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof by administering ammonia oxidizing microorganisms are disclosed. Preparations for treating disorders, including neurodegenerative disorders, neurocognitive disorders, mental disorders, neuropsychological disorders, and symptoms thereof including ammonia oxidizing microorganisms are disclosed. Kits including ammonia oxidizing microorganism preparations and devices for administering ammonia oxidizing preparations are provided. | 2021-02-25 |
20210052673 | Compositions for Fecal Floral Transplantation and Methods for Making and Using Them and Devices for Delivering Them - In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or | 2021-02-25 |
20210052674 | COMPOSITION FOR DIAGNOSIS AND TREATMENT OF ALCOHOLIC LIVER DISEASE, USING CHANGE IN SHORT-CHAIN FATTY ACID PRODUCING GUT BACTERIAL COMMUNITY - The present invention relates to a microorganism which can act as a biomarker of alcoholic fatty liver disease, and relates to a pharmaceutical composition for preventing or treating alcoholic fatty liver disease, a food composition for preventing or improving alcoholic fatty liver disease, or a probiotics composition for preventing or improving alcoholic fatty liver disease, comprising the strain as an active ingredient. | 2021-02-25 |
20210052675 | NANOVESICLES DERIVED FROM BACTERIA OF LACTOCOCCUS GENUS AND USE THEREOF - Provided are vesicles derived from bacteria of the genus | 2021-02-25 |
20210052676 | ANTI-OXIDANT COMPOSITION WITH LACTIC ACID BACTERIUM STRAIN OR FERMENTATION METABOLITE THEREOF AND USES THEREOF - An isolated lactic acid bacterium strain or fermentation metabolite thereof has an anti-oxidant function and is in form of a food composition or a pharmaceutical composition, wherein the isolated lactic acid bacterium strain comprises at least one of an OLP-01 strain of | 2021-02-25 |
20210052677 | BACTERIAL STRAIN USEFUL FOR TREATMENT OF AGE-RELATED CONDITIONS - Provided is a composition comprising an isolated | 2021-02-25 |
20210052678 | POSTBIOTIC-BASED COMPOSITION FOR THE MODULATION OF IMMUNE SYSTEM ACTIVATION AND PROTECTION OF MUCOSAL BARRIERS - The present invention refers to a composition containing a) a fermented supernatant, or fractions thereof, of | 2021-02-25 |
20210052679 | PROBIOTIC DELIVERY OF GUIDED ANTIMICROBIAL PEPTIDES - The present disclosure pertains to a treatment strategy to combat select bacteria in the gut, such as | 2021-02-25 |
20210052680 | Stable Frozen Virus Formulation - A live virus composition that maintains infectivity and provides improved virus stability during one or more freeze/thaw cycles and/or during long term storage in a liquid state at temperatures ranging from just above freezing to ambient temperatures. | 2021-02-25 |
20210052681 | COMPOSITION AND METHOD FOR FORMING A COMPOSITION FOR INCREASING DERMAL NITRIC OXIDE - A composition for increasing dermal nitric oxide comprises in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder suspended in a base suitable for application to the skin of a user. The composition may be formed by providing the base suitable for application to the skin of a user and suspending within the base, in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder. | 2021-02-25 |
20210052682 | Herbal Supplement for Liver Purification - Purification of the liver and removal of toxins from the liver may be improved through the ingestion of an herbal supplement containing a specific composition of materials. The herbal supplement contains an effective amount of | 2021-02-25 |
20210052683 | COMBINATION OF RHODIOLA AND ASTRAGALUS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a product containing an extract of | 2021-02-25 |
20210052684 | METHODS, COMPOSITIONS, AND KITS ADDRESSING DEPRESSED MOOD - A method of treating or preventing postpartum blues or depression is described, comprising administering to a subject in need thereof: an antioxidant source; a tryptophan composition comprising from 1.0 g to 5.0 g of tryptophan; and a tyrosine composition comprising from 2.0 g to 50 g of tyrosine. The antioxidant source may comprise a food or an extract derived from such a food as grapes, berries such as blueberries, citrus fruit, pomegranate, tomato, squash, carrot, sweet potato, dark green vegetables, beets, leafy vegetables, | 2021-02-25 |
20210052685 | NUTRITIONAL SOLID COMPOSITIONS WITH ACARICIDE ACTIVITY FOR APICULTURE AND THEIR USE FOR THE PROPHYLAXIS AND TREATMENT OF VARROA INFESTATIONS - The invention concerns a solid feed composition for use as nourishment for bees and for the prevention and treatment of acariosis, and, in particular, of infestation by | 2021-02-25 |
20210052686 | FRACTION OF MELISSA LEAF EXTRACT HAVING ANGIOGENESIS AND MMP INHIBITORY ACTIVITIES, AND COMPOSITION COMPRISING THE SAME - The present application describes an ethyl acetate fraction of | 2021-02-25 |
20210052687 | PLANT EXTRACT-BASED BIOLOGICALLY ACTIVE SUPPLEMENT HAVING ANTIBACTERIAL, ANTIVIRAL AND ANTIFUNGAL ACTION - The present invention relates to a biologically active supplement formulated in an oral dosage form comprising nutraceutically effective amounts of an extract of | 2021-02-25 |
20210052688 | COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CACHEXIA AND MUSCLE LOSS - The present disclosure relates to a composition containing a Paeoniae radix extract as an active ingredient. The composition may alleviate inappetence, weight loss, muscle loss and fatigue and inhibit hematopoietic toxicity. Thus, the composition may be effectively used for the prevention, alleviation or treatment of cachexia and muscle loss. | 2021-02-25 |
20210052689 | ANTI-MICROBIAL AMALGAMATE OF NON-TOXIC NATIVE COMPOSITION - An anti-microbial formulation of native ingredients for human and non-human vertebrate animal feeds, feed supplements/additives, or for direct doses to replace in whole or supplement traditional anti-microbial with side-effects such as allergies, microbial-resistance, and drug-interactions with non-toxic, side-effect free native anti-microbial for all vertebrates. The invention comprises of non-toxic, side-effect free native substances amalgamations having anti-microbial properties for food additives, food supplements, or direct doses. Furthermore, these native formulas can be use with or without other prescription or nonprescription anti-microbial medications. We describe the method of manufacture and also the process of use for this amalgamates. | 2021-02-25 |
20210052690 | TREATMENT OF HMGB1-MEDIATED INFLAMMATION - Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described. | 2021-02-25 |
20210052691 | METHOD OF TREATING DISEASES - Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal. | 2021-02-25 |
20210052692 | A COMPOSITION FOR TREATING ONE OR MORE ESTROGEN RELATED DISEASES - The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency related side effects, wherein said composition comprises administering a therapeutically effective amount of a Gn RH antagonist to a patient in need of said treatment, and wherein said amount of Gn RH antagonist is sufficient for providing a mean endogenous serum estradiol level of between about 20 pg/ml and 60 pg/ml, preferably between 30 pg/ml and 50 pg/m, in said patient in a treatment period of at least four weeks, without relying on “add-back” therapy. Said composition and method is simple, effective and will accordingly both increase patient acceptance and compliance of therapy. | 2021-02-25 |
20210052693 | PHARMACEUTICAL COMPOSITIONS COMPRISING TEIXOBACTIN - The present invention provides pharmaceutical compositions of teixobactin that are capable of preventing gelation of teixobactin. The pharmaceutical compositions comprise teixobactin and a pegylated phospholipid. The present invention also provides methods of preparing the pharmaceutical compositions of teixobactin and methods of treating a subject using the pharmaceutical compositions of teixobactin. | 2021-02-25 |
20210052694 | COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY - The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (T | 2021-02-25 |
20210052695 | PEPTIDE EXCHANGE PROTEIN - This invention relates to peptide-exchange proteins comprising the luminal domain of TAP-binding protein-related (TAPBPR), which functions as a MHC class I peptide-exchange catalyst when presented to mammalian cells either as a soluble extracellular protein or as a membrane bound cell surface protein. This may be useful in modulating immune responses, including for example loading immunogenic peptide onto tumours or other disease cells to induce their recognition by T cells. Peptide-exchange proteins and methods for their use are provided. | 2021-02-25 |
20210052696 | NOVEL ANTIMICROBIAL PEPTIDE DERIVED FROM LL37 PEPTIDE AND USES THEREOF - A novel antimicrobial peptide derived from LL37 peptide has not only an excellent antimicrobial activity for Gram-positive bacteria, Gram-negative bacteria, and antibiotic tolerant bacteria but also low cytotoxicity for cells derived from mouse or human. It can be advantageously used as an effective component of antimicrobial antibiotics, cosmetic composition, food additive, animal feed additive, biopesticides, and quasi-drug. | 2021-02-25 |
20210052697 | METHOD FOR ISOLATING AND DETECTING CANCER STEM CELLS - Disclosed is the in vitro use of at least one lectin for marking cancer stem cells of hormone-dependent cancer target organs, selected from the lectins | 2021-02-25 |
20210052698 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF - The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension. | 2021-02-25 |
20210052699 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DENTIN-DENTAL PULP DISEASES OR PERIODONTAL DISEASE INCLUDING CPNE4 PROTEIN - Provided are compositions including a CPNE4 protein or a polynucleotide encoding thereof, a pharmaceutical composition, a quasi-drug composition, a dietary supplement, and a health functional food composition. A method for preventing or treating dentin-dental disease or periodontal disease and a method and a method for promoting regeneration of hard tissue including dentin, bone and cementum, and/or pulp tissue are disclosed. | 2021-02-25 |
20210052700 | METHOD FOR TREATING PULMONARY FIBROSIS USING S100A3 PROTEIN - The invention is directed to a method for diagnosing and treating a pulmonary lung disease by detecting a mutant S100A3 protein associated with pulmonary lung disease and by treating a subject with a functional S100A3 protein. | 2021-02-25 |
20210052701 | Methods of Treating Vascular Leakage Using CXCL12 Peptides - The present invention relates to methods for treatment of capillary leak syndrome and acute respiratory distress syndrome using CXCL12 peptides, specifically a constitutively monomeric CXCL12 peptide or a CXCL12 locked dimer polypeptide. | 2021-02-25 |
20210052702 | METHODS OF TREATING MILD BRAIN INJURY - The present disclosure provides methods for treating mild brain injury and other neurological disorders in a subject, comprising administering to the subject an effective amount of a compound comprising ghrelin. | 2021-02-25 |
20210052703 | GLP-1 COMPOSITION FOR TREATING OBESITY AND WEIGHT MANAGEMENT - Disclosed herein is a pharmaceutical composition containing a recombinant human GLP-1 peptide and use thereof. The human GLP-1 peptide and the pharmaceutical composition can be used for preventing or treating obesity, bulimia, and/or overweight. Other related uses include weight management (e.g. inducing weight loss), slowing stomach emptying, increasing satiety, etc. | 2021-02-25 |
20210052704 | INSULIN PREMIX FORMULATION AND PRODUCT, METHODS OF PREPARING SAME, AND METHODS OF USING SAME - A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient. | 2021-02-25 |
20210052705 | METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES - The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu | 2021-02-25 |
20210052706 | COMPOSITIONS AND METHODS FOR FACILITATING DELIVERY OF SYNTHETIC NUCLEIC ACIDS TO CELLS - Provided herein are compositions and methods for facilitating or enhancing delivery of nucleic acids, such as synthetic mRNAs, into cells or tissues. Such compositions and methods may include use of a targeting moiety-conjugated, such as an N-acetylgalactosamine (GalNAc)-conjugated, oligonucleotide to facilitate or enhance delivery. | 2021-02-25 |
20210052707 | ENZYME COMPOSITIONS AND DIAGNOSTICS FOR USE IN ENTEROMETABOLIC DYSFUNCTION - The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME). | 2021-02-25 |
20210052708 | TREATMENT OF INFECTION BY HUMAN ENTEROVIRUS D68 - The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68. | 2021-02-25 |
20210052709 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION - Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to one or more target nucleic acid sequences in a retrovirus genome. | 2021-02-25 |
20210052710 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST AIRBORNE PATHOGENS AND IRRITANTS - The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses. | 2021-02-25 |
20210052711 | BCMA CHIMERIC ANTIGEN RECEPTORS - The invention provides improved compositions for adoptive T cell therapies for B cell related conditions. | 2021-02-25 |
20210052712 | HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT - The present disclosure provides a Farmington virus formulated to induce an immune response in a mammal against a tumour associated antigen. The Farmington virus may express an antigenic protein that includes an epitope from the tumour associated antigen. The Farmington virus may be formulated in a composition where the virus is separate from an antigenic protein that includes an epitope from the tumour associated antigen. The present disclosure also provides a prime:boost therapy for use in inducing an immune response in a mammal. The boost includes a Farmington virus, or a composition that includes a Farmington virus. | 2021-02-25 |
20210052713 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae - The present invention relates to proteins and nucleic acids derived from | 2021-02-25 |
20210052714 | TUBERCULOSIS VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF - The present invention relates to the field of tuberculosis vaccines, and specifically relates to a tuberculosis vaccine, a preparation method thereof, and a use thereof. To address the problem of existing vaccines being unsuitable for patients having weak immunity, the present invention provides a preparation method for a tuberculosis vaccine: first obtaining mycobacterium single cell bacteria, and using low dosage radiation to irradiate cyclically the mycobacterium single cell bacteria, so as to obtain the tuberculosis vaccine. The present invention completely retains all of the antigen characteristics of the bacteria, and can more rapidly stimulate stronger specific immune responses, thereby achieving effective and long-lasting immunity. The vaccine prepared using the present invention has low toxicity, is rapid-acting and safer, and can be used for the prevention and treatment of tuberculosis for people having immunodeficiency. | 2021-02-25 |
20210052715 | IMMUNOMODULATORY MINICELLS AND METHODS OF USE - The present disclosure is related to immunomodulatory bacterial minicells and methods of using the minicells. | 2021-02-25 |
20210052716 | A novel K-serotype Vibrio parahaemolyticus and application - A novel K (capsular antigen) serotype of | 2021-02-25 |
20210052717 | CANCER IMMUNOTHERAPY USING VIRUS PARTICLES - A method of treating cancer in a subject in need thereof includes administering in situ to the cancer a therapeutically effective amount of a virus or virus-like particle. | 2021-02-25 |
20210052718 | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES - Disclosed are vaccines capable of achieving protection against RSV while avoiding vaccine-enhanced disease (VED). In particular, vaccine constructs have been molecularly designed and genetically engineered to comprise RSV fusion (F) protein displayed on the surface of a particle, such as a virus-like particles (VLP) and low temperature-prepared split RSV. In some embodiments, the RSV F protein is in a pre-fusion F conformation. Also disclosed a variants and combinations of split RSV and RSV F DNA vaccine with pre-fusion F and enhanced efficacy. In addition, disclosed split RSV vaccines containing pre-fusion F conformation and combination adjuvants MPL and CpG. | 2021-02-25 |
20210052719 | A UNIVERSAL VACCINE AGAINST INFLUENZA - An antigenic short peptide includes 11 to 15 amino-acid residues and has an ability to induce antibody against influenza virus. The sequence of the antigenic peptide is selected from hemagglutinin (HA). The antigenic peptide includes the sequence of JJ (SEQ ID NO:2), JJ-1 (SEQ ID NO:3), JJ-2 (SEQ ID NO:4), JJ-3 (SEQ ID NO:5) or JJ-4 SEQ ID NO:6). A method for inducing a broad-spectrum immunity against influenza viruses includes administering a vaccine to a subject, wherein the vaccine comprises one of the above antigenic peptide. | 2021-02-25 |
20210052720 | CAP260, CAP174 AND K0224 HIV-1 ENVELOPES, PEPTIDE AND COMPOSITIONS - The invention is directed to HIV-1 envelope proteins and peptides, and compositions comprising the same to increase the breadth of vaccine coverage of the V1 V2 env region of clade C HIV-1. | 2021-02-25 |
20210052721 | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF - The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. | 2021-02-25 |
20210052722 | PEANUT FORMULATIONS AND USES THEREOF - The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy. | 2021-02-25 |
20210052723 | NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR - The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase an immune response. The compounds have general formula (1), wherein R | 2021-02-25 |
20210052724 | METHOD FOR IMPROVING THE EFFICACY OF A SURVIVIN VACCINE IN THE TREATMENT OF CANCER - The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an agent that interferes with DNA replication prior to vaccination with a survivin vaccine. Also provided are compositions for use in the methods of the invention. | 2021-02-25 |
20210052725 | ADJUVANT SYSTEM FOR ORAL VACCINE ADMINISTRATION - The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced T | 2021-02-25 |
20210052726 | TREATMENT OF ASTHMA WITH ANTI-TSLP ANTIBODY - The present disclosure, relates, in general, to methods of treating asthma, including severe asthma and eosinophilic asthma, using an antibody specific for thymic stromal lymphopoietin (TSLP). | 2021-02-25 |
20210052727 | CYTOKINE FUSION PROTEINS - Provided are cytokine fusion proteins comprising a first cytokine fused to a second cytokine, for example, interleukin-2 (IL-2) or interferon-γ (IFN-β) fused to the N-terminus of tumor necrosis factor-α (TNF-α), and related compositions and methods of use thereof for treating cancers, either as standalone agents or in combination with autologous tumor vaccines and/or immune checkpoint modulatory agents. | 2021-02-25 |
20210052728 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer. | 2021-02-25 |
20210052729 | SUPPRESSION OF MYELOID DERIVED SUPPRESSOR CELLS AND IMMUNE CHECKPOINT BLOCKADE - Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors. However, co-treatment with epigenetic modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of them. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). A PI3K-inhibitor that reduced circulating MDSCs also cured 80% of mice with metastatic 4T1 tumors when combined with immune checkpoint inhibitors. Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs. | 2021-02-25 |
20210052730 | Photocleavable Cobalt-Nitrosyl Complex and Nitric Oxide Carrier Containing the Same - The present invention relates to a cobalt-nitrosyl complex having photocleavable ligands. The cobalt-nitrosyl complex provided in one aspect of the present invention is adept in the delivery of NO, with exquisite temporal control using light, without gene editing. In addition, the complex provided in one aspect of the present invention is excellent in biocompatibility because it is chemically stable, non-toxic at cell level, and non-perturbative in cellular environments. | 2021-02-25 |
20210052731 | INORGANIC NANOPHOTOSENSITIZERS AND METHODS OF MAKING AND USING SAME - Provided are nanoparticles surface functionalized with PEG groups and having one or more photosensitizer group. The PEG groups may be functionalized. The nanoparticles may also include therapeutic groups and/or targeting groups. The nanoparticles may be made by hydrolysis of a silica precursor and, optionally, an alumina precursor, in various aqueous reaction mediums. The nanoparticles may be used in photodynamic therapy methods. The methods may also include imaging of an individual. | 2021-02-25 |
20210052732 | CONTROLLED RELEASE MUCOADHESIVE SYSTEMS - Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described. | 2021-02-25 |
20210052733 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY - Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo. | 2021-02-25 |
20210052734 | PEPTIDE-MEDIATED INTRAVESICAL DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS - The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells. | 2021-02-25 |
20210052735 | mTORC1 INHIBITORS - Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1. | 2021-02-25 |
20210052736 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES - The Invention provides a novel delivery system for delivery of drugs across biological membranes. It provides novel chemical conjugates that comprise said delivery system, methods for synthesis of said compounds, and methods for utilization of said delivery system, among others, for delivery of genetic drugs into tissues and cells, in vitro, ex vivo, and in vivo, for the treatment of various medical disorders. | 2021-02-25 |
20210052737 | OPHTHALMIC FORMULATION - The present invention provides an ophthalmic composition comprising an active pharmaceutically compound non-covalently bound to albumin. The composition of the present invention is useful for treatment of ophthalmic diseases and disorders. | 2021-02-25 |
20210052738 | Disulfide Bridging Conjugates - Provided are bispecific conjugates having the general formula: | 2021-02-25 |
20210052739 | HYDROGEL PRODRUG FOR TREATMENT - Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need. | 2021-02-25 |